<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:20:37 -0700</creation_date>
  <update_date>2013-05-27 11:13:10 -0600</update_date>
  <accession>HMDBP09212</accession>
  <secondary_accessions>
    <accession>14994</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>HIF-PH3</synonym>
    <synonym>HIF-prolyl hydroxylase 3</synonym>
    <synonym>HPH-1</synonym>
    <synonym>HPH-3</synonym>
    <synonym>Hypoxia-inducible factor prolyl hydroxylase 3</synonym>
    <synonym>PHD3</synonym>
    <synonym>Prolyl hydroxylase domain-containing protein 3</synonym>
  </synonyms>
  <gene_name>EGLN3</gene_name>
  <general_function>Involved in oxidoreductase activity</general_function>
  <specific_function>Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylation on the NODD site by EGLN3 appears to require prior hydroxylation on the CODD site. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Also hydroxylates PKM in hypoxia, limiting glycolysis. Under normoxia, hydroxylates and regulates the stability of ADRB2. Regulator of cardiomyocyte and neuronal apoptosis. In cardiomyocytes, inhibits the anti-apoptotic effect of BCL2 by disrupting the BAX-BCL2 complex. In neurons, has a NGF-induced proapoptotic effect, probably through regulating CASP3 activity. Also essential for hypoxic regulation of neutrophilic inflammation. Plays a crucial role in DNA damage response (DDR) by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway.
</specific_function>
  <pathways>
    <pathway>
      <name>HIF-1 signaling pathway</name>
      <smpdb_id/>
      <kegg_map_id>map04066</kegg_map_id>
    </pathway>
    <pathway>
      <name>Renal cell carcinoma</name>
      <smpdb_id/>
      <kegg_map_id>map05211</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00725</accession>
      <name>4-Hydroxyproline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00162</accession>
      <name>L-Proline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00044</accession>
      <name>Ascorbic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00208</accession>
      <name>Oxoglutaric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00254</accession>
      <name>Succinic acid</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>vitamin binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>l-ascorbic acid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleoplasm</description>
      <go_id>GO:0005654</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>L-ascorbic acid binding</description>
      <go_id>GO:0031418</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen</description>
      <go_id>GO:0016702</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>peptidyl-proline 4-dioxygenase activity</description>
      <go_id>GO:0031545</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      <go_id>GO:0006919</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>peptidyl-proline hydroxylation to 4-hydroxy-L-proline</description>
      <go_id>GO:0018401</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>protein hydroxylation</description>
      <go_id>GO:0018126</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of cell proliferation</description>
      <go_id>GO:0042127</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of neuron apoptotic process</description>
      <go_id>GO:0043523</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of transcription from RNA polymerase II promoter in response to hypoxia</description>
      <go_id>GO:0061418</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to DNA damage stimulus</description>
      <go_id>GO:0006974</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>Nucleus</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>14</chromosome_location>
    <locus>14q13.1</locus>
    <gene_sequence>&gt;720 bp
ATGCCCCTGGGACACATCATGAGGCTGGACCTGGAGAAAATTGCCCTGGAGTACATCGTG
CCCTGTCTGCACGAGGTGGGCTTCTGCTACCTGGACAACTTCCTGGGCGAGGTGGTGGGC
GACTGCGTCCTGGAGCGCGTCAAGCAGCTGCACTGCACCGGGGCCCTGCGGGACGGCCAG
CTGGCGGGGCCGCGCGCCGGCGTCTCCAAGCGACACCTGCGGGGCGACCAGATCACGTGG
ATCGGGGGCAACGAGGAGGGCTGCGAGGCCATCAGCTTCCTCCTGTCCCTCATCGACAGG
CTGGTCCTCTACTGCGGGAGCCGGCTGGGCAAATACTACGTCAAGGAGAGGTCTAAGGCA
ATGGTGGCTTGCTATCCGGGAAATGGAACAGGTTATGTTCGCCACGTGGACAACCCCAAC
GGTGATGGTCGCTGCATCACCTGCATCTACTATCTGAACAAGAATTGGGATGCCAAGCTA
CATGGTGGGATCCTGCGGATATTTCCAGAGGGGAAATCATTCATAGCAGATGTGGAGCCC
ATTTTTGACAGACTCCTGTTCTTCTGGTCAGATCGTAGGAACCCACACGAAGTGCAGCCC
TCTTACGCAACCAGATATGCTATGACTGTCTGGTACTTTGATGCTGAAGAAAGGGCAGAA
GCCAAAAAGAAATTCAGGAATTTAACTAGGAAAACTGAATCTGCCCTCACTGAAGACTGA
</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>239</residue_number>
    <molecular_weight>27261.06</molecular_weight>
    <theoretical_pi>7.636</theoretical_pi>
    <pfams>
      <pfam>
        <name>2OG-FeII_Oxy</name>
        <pfam_id>PF03171</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Egl nine homolog 3
MPLGHIMRLDLEKIALEYIVPCLHEVGFCYLDNFLGEVVGDCVLERVKQLHCTGALRDGQ
LAGPRAGVSKRHLRGDQITWIGGNEEGCEAISFLLSLIDRLVLYCGSRLGKYYVKERSKA
MVACYPGNGTGYVRHVDNPNGDGRCITCIYYLNKNWDAKLHGGILRIFPEGKSFIADVEP
IFDRLLFFWSDRRNPHEVQPSYATRYAMTVWYFDAEERAEAKKKFRNLTRKTESALTED</protein_sequence>
  </protein_properties>
  <genbank_protein_id>14547150</genbank_protein_id>
  <uniprot_id>Q9H6Z9</uniprot_id>
  <uniprot_name>EGLN3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AJ310545</genbank_gene_id>
  <genecard_id>EGLN3</genecard_id>
  <geneatlas_id>EGLN3</geneatlas_id>
  <hgnc_id>HGNC:14661</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Taylor MS: Characterization and comparative analysis of the EGLN gene family.  Gene. 2001 Sep 5;275(1):125-32.</reference_text>
      <pubmed_id>11574160</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001 Oct 5;107(1):43-54.</reference_text>
      <pubmed_id>11595184</pubmed_id>
    </reference>
    <reference>
      <reference_text>Semenza GL: HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001 Oct 5;107(1):1-3.</reference_text>
      <pubmed_id>11595178</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF.  Science. 2001 Nov 9;294(5545):1337-40. Epub 2001 Oct 11.</reference_text>
      <pubmed_id>11598268</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hutter J, Schramm M, Flamme I: Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun. 2002 Aug 16;296(2):343-9.</reference_text>
      <pubmed_id>12163023</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cioffi CL, Liu XQ, Kosinski PA, Garay M, Bowen BR: Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun. 2003 Apr 11;303(3):947-53.</reference_text>
      <pubmed_id>12670503</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Ascorbic acid</name>
        <accession>HMDB00044</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ascorbic acid</name>
        <accession>HMDB00044</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
